EU pom zoo Wegovy (semaglutide): 18% poob phaus ntawm 68 lub lis piam kho!

Novo Nordisk' cov tshuaj rog rog Wegovy () 2.4mg subcutaneous injection has been approved in the EU, according to the EU New Drug Approval Database: The drug is a once-daily glucagon-like peptide-1 ( GLP-1) analogs for long-term weight management in obese adult patients. Previously, Wegovy was approved by the US FDA in June 2021 and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in September 2021 for long-term weight management. On the US regulatory front, Novo Nordisk submitted a Priority Review Voucher (PRV) to expedite the review.

Qhov tseem ceeb, Wegovy yog thawj zaug thiab tsuas yog ib zaug ib lub lim tiam GLP-1 receptor agonist pom zoo rau kev tswj qhov hnyav hauv cov neeg mob rog. Cov kev pom zoo saum toj no ntawm Wegovy yog raws li cov txiaj ntsig ntawm STEP Phase 3a kev sim tshuaj ntsuam xyuas. Txoj haujlwm no koom nrog ntau dua 4,500 tus neeg mob rog rog lossis rog rog. Hauv kev sim tshuaj ntawm cov neeg uas tsis muaj ntshav qab zib hom 2, cov neeg mob rog rog kho nrog Wegovy poob qhov nruab nrab ntawm 17-18% ntawm lawv lub cev hnyav tshaj 68 lub lis piam. Thoob plaws hauv qhov kev zov me nyuam, Wegovy muaj kev nyab xeeb thiab zam tau zoo, nrog rau cov kev tsis zoo tshwm sim feem ntau yog mob plab.

Kev rog rog yog ib yam kab mob ntev uas yuav tsum tau muaj kev kho mob mus sij hawm ntev thiab cuam tshuam nrog ntau yam kev noj qab haus huv loj thiab txo lub neej expectancy. Cov teeb meem ntsig txog kev rog rog muaj ntau, suav nrog hom 2 mob ntshav qab zib, kab mob plawv, obstructive pw tsaug zog apnea, kab mob raum ntev, kab mob uas tsis yog-coholic fatty siab, thiab mob qog noj ntshav.

Semaglutide yog tib neeg glucagon-zoo li peptide-1 (GLP-1) analogues uas txhawb kev tsim cov tshuaj insulin thiab inhibits glucagon secretion hauv cov piam thaj hauv cov ntshav, uas tuaj yeem txhim kho cov ntshav qabzib ntau hauv cov neeg mob ntshav qab zib hom 2, thiab muaj kev pheej hmoo tsawg. hypoglycemia. Ntxiv rau,semaglutidemuaj peev xwm ua kom poob phaus los ntawm kev txo qis qab los noj mov thiab txo cov khoom noj. Tsis tas li ntawd, semaglutide tuaj yeem txo qhov kev pheej hmoo ntawm cov kab mob plawv loj (MACE) hauv cov neeg mob ntshav qab zib hom 2.

Hauv Suav teb,semaglutide was approved by the NMPA in April 2021 for the treatment of patients with type 2 diabetes (T2D) to improve blood sugar control. Novotel® is a novel long-acting glucagon-like peptide-1 (GLP-1) analog with a half-life of up to 7 days, suitable for weekly injection and stable plasma concentration.

Hauv Suav teb, muaj ntau dua 129.8 lab tus tib neeg muaj ntshav qab zib, ntawm cov uas tsuas yog 15.8% tau ua tiav cov ntshav qab zib. Mob ntshav qab zib tuaj yeem yooj yim ua rau cov kab mob macrovascular, kab mob microvascular thiab lwm yam teeb meem, uas cuam tshuam rau lub neej zoo ntawm cov neeg mob thiab ua rau cov kab mob hnyav ntxiv. Ntawm lawv, kab mob plawv yog qhov ua rau tuag rau cov neeg mob ntshav qab zib hom 2. Hauv Suav teb, 1 ntawm 3 tus neeg mob ntshav qab zib raug mob los ntawm kab mob plawv. Kev tswj cov ntshav qab zib tsis txaus thiab kev tswj xyuas tsis zoo ntawm cov hlab plawv thiab cov metabolism hauv lub cev xws li ntshav siab, ntshav lipids, thiab lub cev hnyav yog qhov laj thawj tseem ceeb rau kev muaj teeb meem loj hauv Suav cov neeg mob ntshav qab zib. Yog li ntawd, kev kho mob ntshav qab zib yuav tsum tau tsom mus rau tag nrho cov txiaj ntsig ntawm cov neeg mob, suav nrog kev tswj ntshav qab zib thiab cov txiaj ntsig ntawm cov hlab plawv, thiab tswj hwm ntau yam kev pheej hmoo.

Raws li cov khoom hnyav GLP-1 uas tuaj yeem muab tshuaj ib zaug ib lub lim tiam,semaglutide